177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE, I0
Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
DBV Technologies Approves 2026 Performance Share Unit Plan for CEO
Bylaw Amendments Following Shareholder Vote at Annual General Meeting
Annual Report to Security Holders
Reports First Quarter 2026 Financial Results
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload